Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE ACETATE versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE ACETATE versus PROMETRIUM.
NORETHINDRONE ACETATE vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial thinning. Also binds to progesterone receptors, exerting antiestrogenic effects.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
Oral, 5 mg once daily for 14 days per cycle, beginning on day 1 of menstrual cycle; for endometriosis, 5 mg daily for 14 days then 10 mg daily for 14 days, then 15 mg daily, or as tolerated up to 15 mg daily continuous.
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Terminal elimination half-life is approximately 5-8 hours (mean 7.5 hours). Clinically, steady-state is achieved within 2-3 days of daily dosing.
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Renal (39-61% as metabolites), biliary/fecal (35-49% as metabolites). Less than 1% excreted unchanged.
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category D/X
Category C
Progestin
Progestin